Reset filter
Keywords
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

1127 Search results.
Relevance Rating New first Old first

Eligibility Kidney Cancer NCT00365768

- 10/3/16 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

Eligibility Colon Cancer NCT01003600

- 12/20/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information; ODM derived from: https://clinicaltrials.gov/show/NCT01003600

Eligibility Colon Cancer NCT00819780

- 12/20/17 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00819780

Eligibility Colon Cancer NCT00890188

- 12/20/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00890188

Eligibility Colon Cancer NCT00411450

- 2/10/17 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT00411450

Eligibility Colon Cancer NCT01239095

- 1/15/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection; ODM derived from: https://clinicaltrials.gov/show/NCT01239095

Eligibility Colon Cancer NCT00193167

- 8/3/16 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00193167

Eligibility Colon Cancer NCT00695201

- 1/10/16 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00695201

Liver and Renal Function After Different Contrast Media NCT01563484 - Eligibility Criteria

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media; ODM derived from: https://clinicaltrials.gov/show/NCT01563484

Eligibility Cancer NCT00752570

- 11/10/17 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00752570

Eligibility NCT00796757 Renal Cell Cancer - Eligibility

- 12/9/13 - 1 form, 2 itemgroups, 10 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00796757

Eligibility Liver Cancer NCT02424955

- 6/29/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation; ODM derived from: https://clinicaltrials.gov/show/NCT02424955

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial